Lynch Thomas L, Kuster Diederik W D, Gonzalez Beverly, Balasubramanian Neelam, Nair Nandini, Day Sharlene, Calvino Jenna E, Tan Yanli, Liebetrau Christoph, Troidl Christian, Hamm Christian W, Güçlü Ahmet, McDonough Barbara, Marian Ali J, van der Velden Jolanda, Seidman Christine E, Huggins Gordon S, Sadayappan Sakthivel
Department of Cell and Molecular Physiology, Loyola University Chicago, Maywood, IL 60153, USA.
Clinical Research Office, Health Sciences Division, Loyola University Chicago, Maywood, IL 60153, USA.
JACC Basic Transl Sci. 2017 Apr;2(2):122-131. doi: 10.1016/j.jacbts.2016.12.001. Epub 2016 Dec 19.
The degradation and release of cardiac myosin binding protein-C (cMyBP-C) upon cardiac damage may stimulate an inflammatory response and autoantibody (AAb) production. We determined whether the presence of cMyBP-C-AAbs associated with adverse cardiac function in CVD patients. Importantly, cMyBP-C-AAbs were significantly detected in ACS patient sera upon arrival to the emergency department, particularly in STEMI patients. Patients positive for cMyBP-C-AAbs had a reduced LVEF and elevated levels of clinical biomarkers of MI. We conclude that cMyBP-C-AAbs may serve as early predictive indicators of deteriorating cardiac function and patient outcome in ACS patients prior to the infarction.
心脏损伤时心肌肌球蛋白结合蛋白C（cMyBP-C）的降解和释放可能会刺激炎症反应和自身抗体（AAb）的产生。我们确定了在心血管疾病（CVD）患者中，cMyBP-C自身抗体的存在是否与不良心脏功能相关。重要的是，在急性冠状动脉综合征（ACS）患者到达急诊科时，其血清中可显著检测到cMyBP-C自身抗体，尤其是在ST段抬高型心肌梗死（STEMI）患者中。cMyBP-C自身抗体呈阳性的患者左心室射血分数（LVEF）降低，心肌梗死临床生物标志物水平升高。我们得出结论，cMyBP-C自身抗体可能作为急性冠状动脉综合征（ACS）患者在梗死前心脏功能恶化和患者预后的早期预测指标。
